Opioid receptors and myocardial protection: do opioid agonists possess cardioprotective effects?

Abstract:

:In an in vivo rat model of myocardial infarction, opioid receptor stimulation has been observed to result in a reduction in infarct size similar to that produced by ischaemic preconditioning. The ability of glibenclamide to abolish this effect suggests an involvement of the myocardial ATP-sensitive potassium (K(ATP)) channel. Importantly, it has recently been demonstrated that glibenclamide can completely abolish the protective effects of preconditioning in humans, suggesting that K(ATP) channel opening may be an endogenous protective mechanism in humans. In this article we report recent findings that indicate that opening of the K(ATP) channel is differentially involved in the antinociceptive effect of some opioids, including buprenorphine, morphine and methadone, but not that of others such as fentanyl or levorphanol. We argue that these findings may also be relevant to the effects of opioids in peripheral tissue, such as the myocardium, and that they may have important clinical ramifications. On the basis of our analysis and interpretation of these in vivo data, we speculate that some opioid agonists, notably buprenorphine, may possess previously unrecognised beneficial cardioprotective effects in some groups of patients, including those undergoing coronary artery bypass and those experiencing an acute myocardial infarction.

journal_name

Clin Drug Investig

authors

McCormack KJ,Chapleo CB

doi

10.2165/00044011-199815050-00009

subject

Has Abstract

pub_date

1998-01-01 00:00:00

pages

445-54

issue

5

eissn

1173-2563

issn

1179-1918

pii

150509

journal_volume

15

pub_type

杂志文章
  • Effectiveness and satisfaction with zolmitriptan 5 mg nasal spray for treatment of migraine in real-life practice: results of a postmarketing surveillance study.

    abstract:OBJECTIVE:Addressing the needs of migraineurs by actively seeking patient feedback on disease-related disability and treatment satisfaction may lead to improved management and treatment outcomes. Patient feedback can be collected in postmarketing surveillance (PMS) studies. The objective of this PMS study was to evalua...

    journal_title:Clinical drug investigation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.2165/00044011-200727010-00005

    authors: Diener HC,Evers S

    更新日期:2007-01-01 00:00:00

  • Combination of Olanzapine and Samidorphan Has No Clinically Significant Effect on the Pharmacokinetics of Lithium or Valproate.

    abstract:BACKGROUND AND OBJECTIVE:Olanzapine is an atypical antipsychotic indicated for the treatment of schizophrenia and, either as monotherapy or as an adjunct to lithium or valproate, for bipolar I disorder. Multiple daily doses of olanzapine do not affect the pharmacokinetics of lithium or valproate; therefore, concomitant...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-019-00860-y

    authors: Sun L,Yagoda S,Yao B,Graham C,von Moltke L

    更新日期:2020-01-01 00:00:00

  • First-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer : analysis of the Italian patients enrolled in the SAiL study.

    abstract:BACKGROUND AND OBJECTIVE:First-line bevacizumab-based therapy has been shown to improve outcomes in patients with advanced non-squamous non-small-cell lung cancer (NSCLC). The recent international phase IV SAiL study (a Study of Avastin [bevacizumab] in combination with platinum-containing chemotherapy in patients with...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s40261-012-0001-9

    authors: Bearz A,Passalacqua R,Alabiso O,Cinieri S,Gridelli C,Cravesana C,Crinò L

    更新日期:2012-11-01 00:00:00

  • Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials.

    abstract:BACKGROUND:Rates and impacts of worsening symptoms in patients with psoriasis have not been well characterized. OBJECTIVES:To assess the risk of clinically relevant worsening of psoriasis symptoms in patients treated with adalimumab versus placebo and to determine the health-related quality-of-life (HRQOL) impacts of ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/11539360-000000000-00000

    authors: Papp KA,Signorovitch J,Ramakrishnan K,Yu AP,Gupta SR,Bao Y,Mulani PM

    更新日期:2011-01-01 00:00:00

  • Lack of bioequivalence between two aciclovir tablets in healthy subjects.

    abstract:OBJECTIVE:This study aimed to compare the systemic bioavailability of two aciclovir tablets, Rouz-Aciclovir (test) and Zovirax (reference), in 12 healthy volunteers. METHODS:In a crossover design, each subject received a single oral dose of aciclovir 400 mg followed by a 7-day washout period. Plasma concentrations of ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.2165/00044011-200828010-00006

    authors: Amini H,Javan M,Gazerani P,Ghaffari A,Ahmadiani A

    更新日期:2008-01-01 00:00:00

  • Efficacy, safety and pharmacokinetics of indacaterol in Caucasian and Japanese patients with chronic obstructive pulmonary disease: a comparison of data from two randomized, placebo-controlled studies.

    abstract:BACKGROUND:Indacaterol is a novel, inhaled, once-daily, ultra-long-acting β2-adrenoceptor agonist that has been approved in the EU for the treatment of chronic obstructive pulmonary disease (COPD). Ethnic differences may influence the pharmacokinetics and pharmacodynamics of a drug, and it is therefore important to com...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.2165/11586520-000000000-00000

    authors: Hosoe M,Woessner R,Matsushima S,Lawrence D,Kramer B

    更新日期:2011-01-01 00:00:00

  • Pattern of Use and Long-Term Safety of Tyrosine Kinase Inhibitors: A Decade of Real-World Management of Chronic Myeloid Leukemia.

    abstract:BACKGROUND AND OBJECTIVES:First-line treatment of chronic phase (CP) chronic myeloid leukemia (CML) is based on the first-generation tyrosine kinase inhibitor (TKI) imatinib or the second-generation TKIs dasatinib or nilotinib. Thanks to the efficacy of TKIs, CML has switched from a fatal to a 'chronic' pathology, and ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-018-0676-7

    authors: Bettiol A,Marconi E,Lombardi N,Crescioli G,Gherlinzoni F,Walley T,Vannacci A,Chinellato A,Giusti P

    更新日期:2018-09-01 00:00:00

  • Barriers to pain management: focus on opioid therapy.

    abstract::Despite the availability of effective pain treatments, there are numerous barriers to effective management resulting in a large proportion of patients not achieving optimal pain control. Chronic pain is inadequately treated because of a combination of cultural, societal, educational, political and religious constraint...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,评审

    doi:10.2165/11630040-000000000-00000

    authors: Zuccaro SM,Vellucci R,Sarzi-Puttini P,Cherubino P,Labianca R,Fornasari D

    更新日期:2012-02-22 00:00:00

  • Generic versus non-generic formulation of extended-release clarithromycin in patients with community-acquired respiratory tract infections: a prospective, randomized, comparative, investigator-blind, multicentre study.

    abstract:BACKGROUND AND OBJECTIVE:There is a general concern about the use of multisource (generic) antibacterials in the clinical setting with registration based solely on bioequivalence data. In order to address this concern, two modified-release formulations of clarithromycin (i.e. the originator Klacid XL and the generic Kl...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.2165/00044011-200929040-00005

    authors: Snyman JR,Schoeman HS,Grobusch MP,Henning M,Rabie W,Hira M,Parshotam K,Mithal Y,Singh S,Ramdas Z

    更新日期:2009-01-01 00:00:00

  • Preferential Antiseizure Medications in Pediatric Patients with Convulsive Status Epilepticus: A Systematic Review and Network Meta-Analysis.

    abstract:BACKGROUND AND OBJECTIVE:The optimal choice for first- and second-line antiseizure medications for pediatric patients with convulsive status epilepticus remains ambiguous. The present study aimed to estimate the comparative effect on the efficacy and safety of different antiseizure medications in pediatric patients wit...

    journal_title:Clinical drug investigation

    pub_type:

    doi:10.1007/s40261-020-00975-7

    authors: Zhang Y,Liu Y,Liao Q,Liu Z

    更新日期:2021-01-01 00:00:00

  • Safety of lornoxicam in the treatment of postoperative pain: a post-marketing study of analgesic regimens containing lornoxicam compared with standard analgesic treatment in 3752 day-case surgery patients.

    abstract:BACKGROUND:Post-marketing surveillance studies can provide supplemental data on the safety of medications in the general population. OBJECTIVE:This study aimed to evaluate the safety of analgesic regimens including the NSAID lornoxicam in the short-term treatment of postoperative pain in a clinically relevant populati...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.2165/11538860-000000000-00000

    authors: Rawal N,Krøner K,Simin-Geertsen M,Hejl C,Likar R

    更新日期:2010-01-01 00:00:00

  • Effect of adverse drug reactions on length of stay in intensive care units.

    abstract::The objective of the present study was to determine the frequency of adverse drug reactions (ADRs) in intensive care units (ICUs) and to evaluate their effect on the length of stay. We performed a prospective study to detect ADRs in 420 patients hospitalised in 10 predetermined beds in the ICU of our hospital between ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-199815040-00011

    authors: Vargas E,Simón J,Martin JC,Puerro M,Gonzalez-Callejo MA,Jaime M,Gomez-Mayoral B,Duque F,Gomez-Delgado A,Moreno A

    更新日期:1998-01-01 00:00:00

  • Safety of Overnight Switch from Brand-Name to Generic Levetiracetam.

    abstract:BACKGROUND AND OBJECTIVE:Concerns that antiepileptic brand-to-generic interchange results in disruption of seizure control are widespread. The objective of this study was to evaluate the safety and tolerability of the brand-to-generic levetiracetam switch in patients with focal or generalized epilepsy. METHODS:A prosp...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-015-0351-1

    authors: Vari MS,Pinto F,Mencaroni E,Giudizioso G,Minetti C,La Neve A,Francavilla T,Piccioli M,Striano S,del Gaudio L,Tovo P,Striano P,Verrotti A

    更新日期:2016-01-01 00:00:00

  • Pharmacokinetic considerations in determining the terminal elimination half-lives of bisphosphonates.

    abstract:BACKGROUND AND OBJECTIVE:Bisphosphonates are commonly used to treat and prevent osteoporosis. These compounds have unusual pharmacokinetic characteristics because they bind strongly to bone, and a portion becomes buried under newly formed bone. Once incorporated into bone tissue, the subsequent release during bone remo...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200525020-00003

    authors: Lasseter KC,Porras AG,Denker A,Santhanagopal A,Daifotis A

    更新日期:2005-01-01 00:00:00

  • Intraocular pressure control with latanoprost/timolol and travoprost/timolol fixed combinations : a retrospective, multicentre, cross-sectional study.

    abstract:OBJECTIVE:The aim of this study was to confirm randomized clinical trial results showing that a fixed timolol/travoprost combination (TT; DuoTrav) controls intraocular pressure (IOP) better than a fixed timolol/latanoprost combination (TL; Xalacom) in everyday ophthalmic practice, when measured in the morning and >24 h...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.2165/0044011-200828120-00004

    authors: Denis P,Lafuma A,Jeanbat V,Laurendeau C,Berdeaux G

    更新日期:2008-01-01 00:00:00

  • Oral Teicoplanin as an Alternative First-Line Regimen in Clostridium difficile Infection in Elderly Patients: A Case Series.

    abstract:BACKGROUND:Elderly patients are more susceptible to Clostridium difficile infections (CDIs). Despite existing guidelines, there is no specific treatment for CDI in geriatrics. Vancomycin is commonly used in the treatment of CDI. Teicoplanin is an alternative glycopeptide which recently received marketing authorization ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-017-0524-1

    authors: Davido B,Leplay C,Bouchand F,Dinh A,Villart M,Le Quintrec JL,Teillet L,Salomon J,Michelon H

    更新日期:2017-07-01 00:00:00

  • Effects of a Novel Aldose Reductase Inhibitor, Fidarestat (SNK-860), on Vibration Perception Threshold and Subjective Symptoms in Patients with Diabetic Polyneuropathy : An Open-Label Pilot Study.

    abstract:OBJECTIVE:To evaluate the effects of fidarestat (SNK-860) on vibration perception threshold, as measured by C64 quantitative tuning fork (64Hz) analysis, as well as its effects on subjective symptoms in patients with diabetic polyneuro-pathy. DESIGN AND SETTING:Open-label, prospective study conducted at 12 hospitals i...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200424110-00006

    authors: Hotta N,Yasuda K,Sumita Y,Sano T,Kakuta H,Nagashima M,Hayashi Y,Yamamoto M,Wakao T,Okuyama M,Kobayashi M,Mori K

    更新日期:2004-01-01 00:00:00

  • Proton pump inhibitors in acute treatment of reflux oesophagitis : a cost-effectiveness analysis.

    abstract:BACKGROUND AND AIM:Gastro-oesophageal reflux disease is a common medical problem that places a significant financial burden on outpatient pharmaceutical expenditure. A substantial proportion of this expenditure can be attributed to the use of proton pump inhibitors (PPIs). The aim of this analysis was to evaluate the c...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200525050-00005

    authors: Lucioni C,Mazzi S,Rossi C

    更新日期:2005-01-01 00:00:00

  • Impact of Formulation on the Pharmacokinetics of Dutasteride: Results from Two Phase I Studies.

    abstract:BACKGROUND AND OBJECTIVES:Dutasteride is currently marketed by GlaxoSmithKline (GSK), either as monotherapy or as a fixed-dose combination with tamsulosin. As part of the project to develop the fixed-dose combination product, alternative formulations of dutasteride were prepared by GSK, and their pharmacokinetic proper...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40261-016-0419-6

    authors: Fossler M,Zhu J,Roehrborn C,McAleese P,Manyak M

    更新日期:2016-09-01 00:00:00

  • Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan.

    abstract::Early initiation of rational and effective combination therapy consisting of antihypertensive drugs with two different and complementary mechanisms of actions is increasingly becoming accepted in clinical practice and by guidelines as a first-line approach to control blood pressure (BP) and prevent cardiovascular outc...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,评审

    doi:10.2165/11538440-000000000-00000

    authors: da Silva PM

    更新日期:2010-01-01 00:00:00

  • The Association between Polypharmacy and Hip Fracture in Osteoporotic Women: A Nested Case-Control Study in South Korea.

    abstract:BACKGROUND AND OBJECTIVE:Polypharmacy, regarded as an indicator of potentially inappropriate medications (PIMs), may lead to a higher risk of serious health consequences in elderly patients with osteoporosis. Thus, this study aimed to analyze the association between polypharmacy and hip fracture in patients with osteop...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-018-0716-3

    authors: Park HY,Kim S,Sohn HS,Kwon JW

    更新日期:2019-01-01 00:00:00

  • Higher risk of sulfonylurea-associated hypoglycemic symptoms in women with type 2 diabetes mellitus.

    abstract:BACKGROUND:Although some evidence suggests that women may be at greater risk for hypoglycemia, no conclusion has been reached, and female sex has not been taken into account in antidiabetic drug-induced hypoglycemia. This study aimed to determine whether females are at a higher risk of sulfonylurea (SU)-associated hypo...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-015-0314-6

    authors: Kajiwara A,Kita A,Saruwatari J,Oniki K,Morita K,Yamamura M,Murase M,Koda H,Hirota S,Ishizuka T,Nakagawa K

    更新日期:2015-09-01 00:00:00

  • The Impact of Ramucirumab on Survival in Patients with Advanced Solid Tumors: A Systematic Review and Meta-Analysis of Randomized II/III Controlled Trials.

    abstract:BACKGROUND AND OBJECTIVES:Ramucirumab is a fully immunoglobulin G (lgG) monoclonal antibody targeting vascular endothelial growth factor receptor type 2 (VEGFR2). Previous clinical trials suggested ramucirumab could improve the survival and increase the risk of adverse effects. Here, we aimed to assess the efficacy and...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,meta分析,评审

    doi:10.1007/s40261-015-0355-x

    authors: Wang K,Qu X,Wang Y,Dong W,Shen H,Zhang T,Ni Y,Liu Q,Du J

    更新日期:2016-01-01 00:00:00

  • Facial Paralysis Following Influenza Vaccination: A Disproportionality Analysis Using the Vaccine Adverse Event Reporting System Database.

    abstract:BACKGROUND AND OBJECTIVE:Several cases of facial paralysis have been reported following influenza vaccination; however, recent surveillance studies have not shown an increased risk. In this study, we analyzed the vaccine adverse event reporting system (VAERS) data to determine whether the facial paralysis reporting rat...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-020-00952-0

    authors: Kamath A,Maity N,Nayak MA

    更新日期:2020-09-01 00:00:00

  • Efficacy and Safety of Fentanyl Citrate Patch, Including a Low-Dose 0.5 mg Formulation, in Opioid-Naïve Patients with Cancer Pain.

    abstract:BACKGROUND AND OBJECTIVE:The use of transdermal fentanyl for opioid-naïve patients is restricted, however, transdermal fentanyl is a useful opioid analgesic for patients in whom oral administration is difficult or for those with renal failure. In this study, the efficacy and safety of fentanyl citrate patches was evalu...

    journal_title:Clinical drug investigation

    pub_type: 临床试验,杂志文章

    doi:10.1007/s40261-020-00965-9

    authors: Yamaguchi S,Uchida E,Terahara T,Okawa K,Hashimoto F,Tanaka Y

    更新日期:2020-11-01 00:00:00

  • Pharmacokinetics, safety, and cardiovascular tolerability of phenylephrine HCl 10, 20, and 30 mg after a single oral administration in healthy volunteers.

    abstract:BACKGROUND AND OBJECTIVES:Phenylephrine HCl 10 mg has been used as a nasal decongestant for over 50 years, yet only limited pharmacokinetic and metabolic data are available. The purpose of this study was to evaluate single-dose pharmacokinetics and safety of phenylephrine HCl 10, 20, and 30 mg and to assess cardiovascu...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40261-015-0311-9

    authors: Gelotte CK,Zimmerman BA

    更新日期:2015-09-01 00:00:00

  • Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in β-Thalassaemia Major Patients: An Italian Perspective.

    abstract:PURPOSE:Deferiprone (DFP), deferasirox (DFX) and deferoxamine (DFO) are used in thalassaemia major (TM) patients to treat chronic iron overload. We evaluated the cost-effectiveness of DFP, compared with DFX and DFO monotherapy, from an Italian healthcare system perspective. METHODS:A Markov model was used over a time ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-017-0496-1

    authors: Pepe A,Rossi G,Bentley A,Putti MC,Frizziero L,D'Ascola DG,Cuccia L,Spasiano A,Filosa A,Caruso V,Hanif A,Meloni A

    更新日期:2017-05-01 00:00:00

  • Amlexanox for the treatment of recurrent aphthous ulcers.

    abstract::Recurrent aphthous ulcer (RAU) is the most prevalent oral mucosal disease in humans, estimated to affect between 5% and 50% of the general population. The minor manifestation of the condition is the most common and is characterised by small, shallow, round or oval lesions that are surrounded by a raised erythematous h...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200525090-00001

    authors: Bell J

    更新日期:2005-01-01 00:00:00

  • Safety and Feasibility of Treatment with Rivaroxaban for Non-Canonical Indications: A Case Series Analysis.

    abstract:BACKGROUND AND OBJECTIVES:The new oral anticoagulants (NOACs) are used for the prevention of thromboembolic complications in patients with non-valvular atrial fibrillation (AF) and those at risk of deep venous thrombosis. Their rapid onset of action and predictable pharmacokinetic and pharmacodynamic profiles make them...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-016-0436-5

    authors: Acanfora D,Acanfora C,Scicchitano P,Longobardi M,Furgi G,Casucci G,Lanzillo B,Dentamaro I,Zito A,Incalzi RA,Ciccone MM

    更新日期:2016-10-01 00:00:00

  • Determining clinically important changes in range of motion in patients with Dupuytren's Contracture: secondary analysis of the randomized, double-blind, placebo-controlled CORD I study.

    abstract:BACKGROUND AND OBJECTIVE:Injectable collagenase Clostridium histolyticum is efficacious in correcting Dupuytren's contracture as assessed by changes in the angle of contracture and range of motion (ROM). However, clinically important changes in ROM have not been evaluated in depth. The objective of this secondary analy...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/BF03256918

    authors: Witthaut J,Bushmakin AG,Gerber RA,Cappelleri JC,Le Graverand-Gastineau MP

    更新日期:2011-11-01 00:00:00